Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Standard Precaution01:26

Standard Precaution

Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Council's Tackling Tobacco program: an Australian initative building partnerships for public health research impact.

Public health research & practice·2026
Same author

Exploring the benefits and challenges of lived and living experience among support workers in the alcohol, drug and mental health workforce in Australia.

The International journal on drug policy·2026
Same author

Lattice Radiation Therapy Delays Progression and Extends Survival for Dogs with Macroscopic Soft Tissue Sarcoma.

Radiation research·2026
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

Improving cosmological reach of a gravitational wave observatory using Deep Loop Shaping.

Science (New York, N.Y.)·2025

Related Experiment Video

Updated: Jun 25, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Non-occupational postexposure prophylaxis for HIV: a systematic review.

J Bryant1, L Baxter, S Hird

  • 1Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, University of Southampton, Southampton, UK.

Health Technology Assessment (Winchester, England)
|February 25, 2009
PubMed
Summary

Limited evidence exists for the clinical effectiveness of non-occupational post-exposure prophylaxis (PEP) for HIV. However, HIV PEP may be cost-effective for specific high-risk groups, though results require cautious interpretation due to data limitations.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Related Experiment Videos

Last Updated: Jun 25, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Area of Science:

  • Public Health
  • Infectious Disease Epidemiology
  • Health Economics

Background:

  • Non-occupational post-exposure prophylaxis (PEP) is a strategy to prevent HIV infection after potential exposure.
  • Evidence regarding the clinical effectiveness and cost-effectiveness of non-occupational PEP is crucial for public health policy.
  • Previous reviews have highlighted the need for robust data on PEP's impact in diverse risk groups.

Purpose of the Study:

  • To systematically review the available evidence on the clinical effectiveness of non-occupational PEP for HIV.
  • To evaluate the cost-effectiveness of non-occupational PEP across various risk behaviors and demographic groups.
  • To synthesize findings to inform clinical practice and policy regarding HIV prevention.

Main Methods:

  • A comprehensive literature search was conducted across eleven electronic databases up to December 2007.
  • Included studies underwent rigorous assessment, data extraction, and quality evaluation.
  • A narrative synthesis approach was employed to integrate findings from all eligible studies.

Main Results:

  • Only one weak-quality clinical effectiveness study was identified, showing no significant difference in seroincidence between PEP and non-PEP groups.
  • Four economic evaluations suggested that non-occupational PEP could be cost-saving or cost-effective for specific high-risk populations, including men who have sex with men and intravenous drug users.
  • Adverse events, primarily nausea and fatigue, were common, with higher rates in triple therapy regimens, impacting treatment completion.

Conclusions:

  • Insufficient evidence prevents definitive conclusions on the clinical effectiveness of non-occupational PEP for HIV.
  • Non-occupational PEP demonstrates potential cost-effectiveness in certain subgroups, but findings should be interpreted cautiously due to methodological limitations and data constraints.
  • Further high-quality research is needed to establish the definitive clinical effectiveness and optimize the use of non-occupational PEP.